Prosecution Insights
Last updated: November 20, 2026
Application No. 18/686,954

FUNCTIONALIZED, DECELLULARIZED CORNEAL EXTRACELLULAR MATRIX HYDROGELS FOR OCULAR TISSUE TREATMENT

Non-Final OA §103
Filed
Feb 27, 2024
Priority
Sep 02, 2021 — provisional 63/240,054 +1 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Board of Trustees of the University of Illinois
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
2m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
465 granted / 760 resolved
+1.2% vs TC avg
Strong +32% interview lift
Without
With
+32.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
65 currently pending
Career history
823
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Applicant's election with traverse of Group I, methyl acrylate, Eosin Y, and a composition comprising decellularized porcine corneal tissue functionalized with methacrylate anhydride and photo-initiated with Eosin Y as a photoinitiator, triethanolamine as a co-initiator and N-vinylcaprolactam as a co-monomer in the reply filed on 9/23/2026 is acknowledged. Applicant did not provide any arguments. The requirement is still deemed proper and is therefore made FINAL. Applicants elected species (i.e. a composition comprising decellularized porcine corneal tissue functionalized with methacrylate anhydride and photo-initiated with Eosin Y as a photoinitiator, triethanolamine as a co-initiator and N-vinylcaprolactam as a co-monomer) was deemed to be free of the prior art. The search was extended to another species. As a result, claims 1 and 4 have been examined and claims 2-3 and 5-12 are withdrawn from consideration. While applicant’s elected species may read on one or more withdrawn claims, they have not been fully examined for patentability, and thus a determination of allowability cannot be made with respect to these claims at this time. Status of the Claims Claims 1-12 are pending in this application. Claims 2-3 and 5-12 are withdrawn from consideration as being drawn to a non-elected species/invention. Claims 1 and 4 are presently under consideration as being drawn to the elected species/invention. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1 and 4 are rejected under 35 U.S.C. 103 as being unpatentable over Ahearne et al. (Tissue Eng Part C Methods. 2015 Oct;21(10):1059-69) and Sani et al. (Sci Adv. 2019 Mar 20;5(3):eaav1281). With respect to claim 1, Ahearne et al. teach hydrogels fabricated from decellularized corneal extracellular matrix for corneal stroma regeneration (abstract). Ahearne et al. also teach that the elastic modulus of the hydrogels appears quite low when compared to native corneal tissue (page 1067, left column, 4th para). Ahearne et al. further teach that “[S]everal studies have applied different crosslinking techniques to improve the mechanical properties of hydrogels such as UV A-riboflavin crosslinking and these could be used to improve the materials' mechanical strength. This crosslinking approach should be particularly beneficial for CMHs since a significant quantity of the collagen within the hydrogels was removed during media changes and additional crosslinking would be expected to help retain more collagen within the hydrogel” (page 1067, left column, 5th para). Ahearne et al. do not teach that the decellularized corneal extracellular matrix is functionalized with an acrylate. Sani et al. teach that a transparent, flexible, and adhesive photocrosslinkable hydrogel for the treatment of corneal stromal defects is obtained by reacting a gelatin solution with methacrylic anhydride (abstract; page 11, right column, 2nd para; figure 1 A). Sani et al. also teach that “[T]he visible light cross-linking scheme has been proven to improve cell viability, compared to UV cross-linked systems. Briefly, the visible light photons excite the photoinitiator molecules (Eosin Y) to a triplet state, which allow them to accept hydrogen atoms from coinitiator molecules (TEA). The deprotonated radicals then undergo vinyl-bond cross-linking with co-monomer (VC) via chain polymerization. This will result in accelerated gelation of the polymeric scaffolds. This visible light photocrosslinking chemistry is an FDA-approved system and has been used previously as a safe photocrosslinking system for biomedical applications” (para bridging left and right columns on page 2). It would have been obvious to one of ordinary skill in the art to functionalize the decellularized corneal extracellular matrix of Ahearne et al. with methacrylic anhydride (i.e. methacrylic anhydride) because Sani et al. teach that a transparent, flexible, and adhesive photocrosslinkable hydrogel for the treatment of corneal stromal defects is obtained by reacting a gelatin solution with methacrylic anhydride. The skilled artisan would have been motivated to do so, with a reasonable expectation of success, because Ahearne et al. suggest applying different crosslinking techniques in order to improve the mechanical properties of hydrogels. With respect to claim 4, the MPEP 2144.05 A states that “[G]enerally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997)”. Since Applicant has not disclosed that the specific limitations recited in the instant claims are for any particular purpose or solve any stated problem, absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum weight ratio of decellularized corneal extracellular matrix to acrylate by normal optimization procedures known in the pharmaceutical art. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Feb 27, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799165
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 2m to grant Granted Nov 17, 2026
Patent 12790379
METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASE USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
4y 1m to grant Granted Nov 10, 2026
Patent 12790374
METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES
2y 9m to grant Granted Nov 10, 2026
Patent 12780871
POLYPEPTIDES RV3 AND RV4 HAVING ANTI-AGING FUNCTION AND APPLICATIONS THEREOF
4y 7m to grant Granted Nov 03, 2026
Patent 12780877
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 1m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+32.3%)
2y 11m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month